Ortikos vs. Entyvio

• Are Ortikos and Entyvio the Same Thing?
• What Are Possible Side Effects of Ortikos?
• What Are Possible Side Effects of Entyvio?
• What Is Ortikos?
• What Is Entyvio?
• What Drugs Interact with Ortikos?
• What Drugs Interact with Entyvio?
• How Should Ortikos Be Taken?
• How Should Entyvio Be Taken?

Ortikos (budesonide) and Entyvio (vedolizumab) are used to treat active Crohn's disease.

Ortikos is used to treat mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, in patients 8 years and older; and for maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months in adults.

Entyvio is used to treat moderate to severe active Crohn's disease (CD) and also to treat moderate to severe active ulcerative colitis (UC).

Ortikos and Entyvio belong to different drug classes. Ortikos is a corticosteroid and Entyvio is an IgG1 monoclonal antibody.

Side effects of Ortikos and Entyvio that are similar include headache, respiratory infection, nausea, back pain, and fatigue.

Side effects of Ortikos that are different from Entyvio include indigestion/heartburn, dizziness, abdominal pain, gas (flatulence), vomiting, and pain.

Side effects of Entyvio that are different from Ortikos include common cold symptoms (runny or stuffy nose, sinus pain, sneezing, cough), joint pain, fever, infections of the nose and throat, tiredness, bronchitis, flu symptoms, rash, itching, sinus infection, sore throat, and pain in your arms or legs.

Ortikos may interact with CYP3A4 Inhibitors (e.g., ketoconazole, grapefruit juice, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine).

Entyvio may interact with natalizumab, TNF blockers, and "live" vaccines.

Common side effects of Ortikos include:

• headache,
• respiratory infection,
• nausea,
• back pain,
• indigestion/heartburn,
• dizziness,
• abdominal pain,
• gas (flatulence),
• vomiting,
• fatigue, and
• pain

Common side effects of Entyvio include:

• common cold symptoms (runny or stuffy nose, sinus pain, sneezing, cough),
• headache,
• joint pain,
• nausea,
• fever,
• infections of the nose and throat,
• tiredness,
• fatigue,
• upper respiratory tract infection,
• bronchitis,
• flu symptoms,
• back pain,
• rash,
• itching,
• sinus infection,
• sore throat, and
• pain in your arms or legs.

Ortikos (budesonide) is a corticosteroid indicated for treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon, in patients 8 years and older; and maintenance of clinical remission of mild to moderate Crohn' disease involving the ileum and/or the ascending colon for up to 3 months in adults.

Entyvio (vedolizumab) is an IgG1 monoclonal antibody used to treat moderate to severe active ulcerative colitis (UC) and moderate to severe active Crohn's disease (CD).

Ortikos may interact with CYP3A4 Inhibitors (e.g., ketoconazole, grapefruit juice, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, and cyclosporine). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Ortikos; it may harm a fetus.

Entyvio may interact with natalizumab, TNF blockers, and "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Entyvio. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

The recommended adult dosage of Ortikos for mild to moderate active Crohn's disease is 9 mg once daily for up to 8 weeks; repeat 8-week treatment courses recurring episodes of active disease. The recommended dosage of Ortikos for pediatric patients 8 to 17 years who weigh more than 25 kg is 9 mg once daily for up to 8 weeks, followed by 6 mg once daily in the morning for 2 weeks.

The recommended dosage of Entyvio in adults with ulcerative colitis or Crohn's disease is 300 mg administered by intravenous infusion at zero, two, and six weeks, and then every eight weeks thereafter.